JP Morgan Chase
CYT

JP Morgan Chase’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

JP Morgan Chase’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-124
Closed -$377 – 8041
2023
Q4 		$377 Sell
124
-372
-75% -$1.13K ﹤0.01% 6962
2023
Q3 		$1.41K Hold
496
– – ﹤0.01% 6596
2023
Q2 		$1.29K Hold
496
– – ﹤0.01% 6421
2023
Q1 		$1K Hold
496
– – ﹤0.01% 6580
2022
Q4 		$1K Sell
496
-1,536
-76% -$2.46K ﹤0.01% 6469
2022
Q3 		$4K Buy
2,032
+614
+43% +$1.6K ﹤0.01% 6163
2022
Q2 		$4K Sell
1,418
-11,519
-89% -$29.4K ﹤0.01% 6219
2022
Q1 		$49K Buy
12,937
+6,616
+105% +$37.7K ﹤0.01% 5808
2021
Q4 		$71K Buy
6,321
+1,903
+43% +$29K ﹤0.01% 5815
2021
Q3 		$77K Buy
+4,418
New +$82.6K ﹤0.01% 5695

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

JP Morgan Chase's CYT Position: Q1 2024 in Review

JP Morgan Chase sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 124 shares — an estimated $377 sold.

JP Morgan Chase first reported a position in CYT in Q3 2021 and held it in 10 quarters. The position peaked at $77K in Q3 2021. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • JP Morgan Chase reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • JP Morgan Chase sold 124 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $377.
  • JP Morgan Chase first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q3 2021 and held it in 10 quarters.
  • JP Morgan Chase's Cyteir Therapeutics, Inc. Common Stock position peaked at $77K in Q3 2021.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.